NRI is excited to share these clinically relevant results for the efficacy and safety of Exenatide plus Dapagliflozin for patients with uncontrolled type 2 diabetes taking Metformin. We are proud to focus on diseases that affect our community and see great results such as these!
https://care.diabetesjournals.org/content/43/10/2528.long
clinic_doc
16
Oct2020
08
Oct2020
Take a look at our latest publication. We are honored to share the results from our involvement in this important T2DM study. https://www.tandfonline.com/doi/pdf/10.1080/17446651.2020.1830759?needAccess=true
22
Sep2020
NRI has been a proud contributor to the Pfizer COVID-19 vaccine trial! We believe that it is our obligation to help our communities find solutions to the COVID-19 crisis. We are honored when our patients agree to volunteer to participate and then take the time to provide us with valuable ... Read More
13
Aug2020
Patients at high risk for coronavirus should watch out for this common liver condition, doctor warns. Read article here.
06
Aug2020
Mark Leibowitz, M.D., Chief Medical Officer will lead National Research Institute’s study program with Eli Francisco, Senior Project Manager
Potential participants can visit https://www.covidvaccinestudy.com/#about-the-study to learn more about local enrollment criteria
Los Angeles, CA, August 06, 2020— National Research Institute (NRI) today announced plans to participate as a study site for, ... Read More
15
Jul2020
Checkout this article published in the American Diabetes Association’s Diabetes Care issue regarding the comparison of “Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes”. It’s an honor to share the involvement of Dr. Frias and NRI in this important study! ... Read More
20
May2020
Clinical Trials Day is a special day to recognize the people who conduct clinical trials and thank them for improving public health. This day is also an opportunity to raise awareness about clinical trials.
We'd like to thank and celebrate all clinical research professionals, including our very own at NRI, for ... Read More
11
May2020
We are excited to share some great work from Dr. Frias and the NRI team regarding Dulaglutide’s significant results tied to A1C and weight reduction in diabetes. We are so proud of the valuable results from of our involvement with this Eli Lilly study.
https://medicaldialogues.in/diabetes-endocrinology/news/higher-doses-of-dulaglutide-reduces-blood-sugar-and-weight-in-diabetes-65621
07
May2020
Results showed a statistical significant reduction in liver fat in patients with NASH and diabetes. Our contribution to this important study is what makes us proud of what we do!
https://www.businesswire.com/news/home/20200507005019/en/HighTide-Therapeutics-Announces-Positive-Topline-Results-Phase
06
May2020
Axcella announces top-line data from AXA1125-003 clinical study on adult subjects with NAFLD. Exciting news to share as contributors to this study!
https://ir.axcellahealth.com/news-releases/news-release-details/axcella-announces-positive-top-line-data-axa1125-003-clinical